Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 1302-7 is a short (typically 20–24 nucleotides) non-coding RNA, transcribed by RNA polymerase II and processed by Drosha and Dicer enzymes to form mature miRNA. Mature microRNAs participate in gene silencing by base-pairing with target messenger RNAs, leading to translational inhibition or mRNA degradation via the RNA-induced silencing complex (RISC)[2]. The miR-1302 family is human-specific and derives from MER53 transposable elements that generate paralogous miRNAs across the genome[1]. While functional studies of individual family members—such as MIR1302-7—are limited, they are predicted to regulate genes involved in cellular organization, localization, and development, chiefly by affecting transcriptional regulation and various cellular processes[1]. No direct therapeutic interventions targeting MIR1302-7 are recorded, and its specific biological roles or disease associations are still under investigation. Thus, it is classified as a non-coding RNA regulator rather than a conventional therapeutic target[2][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 1302-7 (MIR1302-7).